BridgeBio Oncology Therapeutics (BBOT) raised $200m in a private financing round led by Cormorant Asset Management and Omega Funds to expedite precision oncology pipeline development.
BridgeBio Pharma has announced the launch of BridgeBio Oncology Therapeutics (BBOT), supported by $200m of private external capital to expedite the development of the company’s precision oncology pipeline, focusing on new cancer treatments.
Who to call at BridgeBio, and when
A new round usually means BridgeBio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day BridgeBio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at BridgeBio, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
BridgeBio
Location
Palo Alto, California, United States
About
BridgeBio Oncology Therapeutics (BBOT) has launched with a $200m private financing round, aiming to expedite the development of the company’s precision oncology pipeline and focusing on new cancer treatments.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BridgeBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Palo AltoBiotechnologyHealth CareTherapeutics